Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

Healthcare Biotechnology
iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Satellos Bioscience Inc Com
Bullboard Posts
User Avatar Image
(0)
•••
Comment by stockgurukingon Oct 04, 2012 10:48am
196 Views
Post# 20447043

RE: RE: RE: RE: SRPT

RE: RE: RE: RE: SRPT

TB, yes just a hunch and I could be wrong, but as we know clinicians like to make a lot of noise about their successes when their peers are around and the ophthalmic conferences are an ideal place to do just that.  These conferences are also a hotbed for pharmas that are out scouting the latest and greatest technologies and advancements in the space.

-

Dr. Quan Nguyen (the trial's lead clinician) is a name that is synonymous with this space and with high profile collaborators like JDRF, John Hopkins University and many of the TOP eye centers in the US intimately involved with the trial you can bet the marketing machines will be in high gear this Fall!

 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities